Monash announces collaboration with Johnson & Johnson innovation for rheumatoid arthritis detection and treatment—5 June 2017

Facilitating research into the early detection and prevention of rheumatoid arthritis that has been supported by the Australian Research Council, Monash University has signed a major multiyear research and commercialisation deal with Janssen Biotech, Inc. (“Janssen”), one of the Janssen Pharmaceutical companies of Johnson & Johnson.

Rheumatoid arthritis is a debilitating autoimmune disease that affects more than 400,000 Australians and more than 24.5 million people worldwide. The agreement has the potential to deliver significant benefit to community, industry and research.

Led by ARC Australian Laureate Fellow, Professor Jamie Rossjohn, the research team at the Monash Biomedicine Discovery institute has been investigating the impact of therapeutics on immune systems affected by rheumatoid arthritis. “This collaboration is a great opportunity to take our advances in basic biomedical science and translate them to the market for the betterment of the Australian population and worldwide,” Professor Rossjohn said.

Deputy Vice-Chancellor (Enterprise), Ken Sloan, said the strategic partnership with Janssen is another example of Monash actively engaging with industry in order to translate its world-leading research. “Monash University is at the heart of Melbourne’s flourishing south east corridor and collaborations such as these are accelerated through our proximity to major biomedical research infrastructure such as the Australian Synchrotron, Monash Biomedical Imaging and other research facilities such as CSIRO, which is helping create a pipeline of translation from basic research to commercialisation, and making Monash a preferred partner for industry,” Mr Sloan said.

Media issued by Monash University.

Image: Monash Biomedicine Discovery Institute.
Image: Monash University.

Original Published Date: 
Monday, June 5, 2017